Literature DB >> 32236519

Lenalidomide in follicular lymphoma.

Christopher R Flowers1, John P Leonard2,3, Nathan H Fowler1.   

Abstract

Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as a first-line therapy and as a treatment of patients with relapsed/refractory follicular lymphoma. Lenalidomide-rituximab has been demonstrated to be an effective chemotherapy-free therapy that improves upon single-agent rituximab and may become an alternative to chemoimmunotherapy.
© 2020 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32236519      PMCID： PMC7290094          DOI： 10.1182/blood.2019001751

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  21 in total

1.  Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.

Authors:  Emanuele Zucca; Stephanie Rondeau; Anna Vanazzi; Bjørn Østenstad; Ulrich J M Mey; Daniel Rauch; Björn E Wahlin; Felicitas Hitz; Micaela Hernberg; Ann-Sofie Johansson; Peter de Nully Brown; Hans Hagberg; Andrés J M Ferreri; Andreas Lohri; Urban Novak; Thilo Zander; Hanne Bersvendsen; Mario Bargetzi; Walter Mingrone; Fatime Krasniqi; Stefan Dirnhofer; Stefanie Hayoz; Hanne Hawle; Simona Berardi Vilei; Michele Ghielmini; Eva Kimby
Journal:  Blood       Date:  2019-05-17       Impact factor: 22.113

2.  Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Authors:  Sonali M Smith; Brandelyn N Pitcher; Sin-Ho Jung; Nancy L Bartlett; Nina Wagner-Johnston; Steven I Park; Kristy L Richards; Amanda F Cashen; Anthony Jaslowski; Scott E Smith; Bruce D Cheson; Eric Hsi; John P Leonard
Journal:  Lancet Haematol       Date:  2017-03-15       Impact factor: 18.959

3.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Authors:  Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly
Journal:  Lancet       Date:  2010-12-20       Impact factor: 79.321

4.  Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

Authors:  Gilles Salles; Nicolas Mounier; Sophie de Guibert; Franck Morschhauser; Chantal Doyen; Jean-François Rossi; Corinne Haioun; Pauline Brice; Béatrice Mahé; Reda Bouabdallah; Bruno Audhuy; Christophe Ferme; Caroline Dartigeas; Pierre Feugier; Catherine Sebban; Luc Xerri; Charles Foussard
Journal:  Blood       Date:  2008-09-17       Impact factor: 22.113

5.  Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

Authors:  John P Leonard; Sin-Ho Jung; Jeffrey Johnson; Brandelyn N Pitcher; Nancy L Bartlett; Kristie A Blum; Myron Czuczman; Jeffrey K Giguere; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

6.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

7.  Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

Authors:  Thomas E Witzig; Peter H Wiernik; Timothy Moore; Craig Reeder; Craig Cole; Glen Justice; Henry Kaplan; Michael Voralia; Dennis Pietronigro; Kenichi Takeshita; Annette Ervin-Haynes; Jerome B Zeldis; Julie M Vose
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

8.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

Authors:  Michael Herold; Antje Haas; Stefanie Srock; Sabine Neser; Kathrin Haifa Al-Ali; Andreas Neubauer; Gottfried Dölken; Ralph Naumann; Wolfgang Knauf; Mathias Freund; Robert Rohrberg; Klaus Höffken; Astrid Franke; Thomas Ittel; Erika Kettner; Ursula Haak; Ulrich Mey; Christian Klinkenstein; Michael Assmann; Ullrich von Grünhagen
Journal:  J Clin Oncol       Date:  2007-04-09       Impact factor: 44.544

9.  Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Authors:  Franck Morschhauser; Nathan H Fowler; Pierre Feugier; Reda Bouabdallah; Hervé Tilly; M Lia Palomba; Christophe Fruchart; Edward N Libby; Rene-Olivier Casasnovas; Ian W Flinn; Corinne Haioun; Hervé Maisonneuve; Loic Ysebaert; Nancy L Bartlett; Kamal Bouabdallah; Pauline Brice; Vincent Ribrag; Nicolas Daguindau; Steven Le Gouill; Gian M Pica; Alejandro Martin Garcia-Sancho; Armando López-Guillermo; Jean-François Larouche; Kiyoshi Ando; Maria Gomes da Silva; Marc André; Pierre Zachée; Laurie H Sehn; Kensei Tobinai; Guillaume Cartron; David Liu; Jianming Wang; Luc Xerri; Gilles A Salles
Journal:  N Engl J Med       Date:  2018-09-06       Impact factor: 91.245

10.  A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Authors:  P Martin; S-H Jung; B Pitcher; N L Bartlett; K A Blum; T Shea; E D Hsi; J Ruan; S E Smith; J P Leonard; B D Cheson
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976
View more
  5 in total

Review 1.  Lenalidomide: A Review in Previously Treated Follicular Lymphoma.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

2.  Lenalidomide improves H2O2-induced PC12 cell injury by blocking the Notch signaling pathway.

Authors:  Zheng Lv; Shao Yin; Ziguan Cheng; Kekai Wang
Journal:  Exp Ther Med       Date:  2022-04-29       Impact factor: 2.447

3.  Identification of Hub Genes and Key Pathways Associated with Follicular Lymphoma.

Authors:  Qing Zhang; Meng Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-07-31       Impact factor: 3.009

Review 4.  Rare central nervous system lymphomas.

Authors:  Furqaan Ahmed Kaji; Nicolás Martinez-Calle; Vishakha Sovani; Christopher Paul Fox
Journal:  Br J Haematol       Date:  2022-03-16       Impact factor: 8.615

Review 5.  Ikaros Proteins in Tumor: Current Perspectives and New Developments.

Authors:  Ruolan Xia; Yuan Cheng; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  Front Mol Biosci       Date:  2021-12-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.